• Lilly Announces Top-Line Phase 3 Results for Baricitinib Trial americanpharmaceuticalreview
    February 19, 2019
    Eli Lilly and Company and Incyte announced baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with ....
PharmaSources Customer Service